Article

Coagulation monitoring of VKA treatment and the benefits of INR self-testing

Published on December 16, 2025 | 4 min read
A doctor is sitting at a desk and holding a CoaguChek instrument which he is showing to a patient

Key takeaways

  • Due to a narrow therapeutic window, individually varying half-lives and nutrition-dependent blood levels of available VKAs, coagulation monitoring is key to ensure an effective and safe therapy for you
  • Coagulation is measured using the International Normalized Ratio (INR) value, and regular monitoring of the INR level is important to determine if your anticoagulant treatment dose needs to be adjusted
  • INR self-testing with CoaguChek enables you to monitor your INR at home and share your results with your doctor, meaning therapy decisions can be made with minimal disruption to your everyday life

Make the right choice for you when you need coagulation monitoring

Anticoagulant treatment can be prescribed for a number of different conditions. Understanding your treatment and the tools available can help you gain better control of your anticoagulation therapy. Coagulation monitoring is an essential part of treatment, and the use of INR self-testing can help you to spend less time on appointments and more time on what matters to you.

Anticoagulation treatment: Why are anticoagulants prescribed?

The human body has a complex mechanism called coagulation that causes blood to clot if a wound occurs. Under normal circumstances, this is desirable, as it allows the body to heal itself. Yet in some clinical conditions, coagulation can cause unwanted blood clots that may lead to complications and can be life-threatening. Oral anticoagulants, such as warfarin and phenprocoumon, are used to prevent blood clots and are often referred to as "blood thinners".

Anticoagulants are commonly prescribed for the following conditions:1-3

  • Atrial fibrillation (irregular heartbeat)
  • Mechanical heart valves
  • Stroke
  • Venous thromboembolism
  • Thrombophilia (tendency to cause blood clots)
  • Moderate-to-high degree of mitral valve stenosis

What are INR values and why are they important?

When prescribed anticoagulation therapy, such as the use of a vitamin K antagonist (VKA), taking the correct dose is crucial for effective treatment. The correct dose is established by measuring how long it takes your blood to clot. This is called the International Normalized Ratio (INR).4 An INR of 1 is normal in healthy individuals who are not taking anticoagulants.5 An INR of 2 means that your blood takes twice as long to clot as normal.5

The therapeutic INR range for patients on anticoagulation therapy can vary depending on the indication VKAs are prescribed for. However, the target range is commonly between 2.0–3.0.5-7 If the INR is too low, there is an increased risk of blood clots that can lead to stroke.8,9 If the INR is too high, there is an increased risk of bleeding.8 Regularly monitoring INR levels is important to help determine if your dose needs to be adjusted. Your doctor will provide you with a target INR range. For people taking VKAs, which include warfarin, the target INR typically ranges from 2 to 3, but may be different depending on the patient and his or her condition.5-7

Vitamin K antagonists (VKAs) at a glance

Considerations

  • VKAs belong to the group of most frequently used drugs worldwide10
  • Must be regularly monitored10
  • May be prescribed for a period of weeks, months, or lifelong

How it's administered

  • Oral tablet

Available VKAs

  • Warfarin
  • Phenprocoumon
  • Acenocoumarol
A man holding a CoaguChek instrument and inserting a test strip into the instrument to measure blood coagulation

How testing at home can help you

It is important to keep your blood clotting time within the range prescribed by your doctor. You may need to take your anticoagulant for a few weeks, months, or even for the rest of your life. But no matter how long, your levels need to be regularly measured, and that’s where INR self-testing is a great benefit.

At-home testing with an INR machine can give you better control of your medication than testing at a laboratory or doctor’s office, with more time in your therapeutic range.11-16 INR monitoring at home only requires a drop of blood, and results are available in about a minute.17 Results can either be reported to your doctor or nurse, who will adjust your dose for you, or you can learn how to adjust the dose yourself. Have peace of mind that you know your INR value when needed, at home or away.

INR self-testing with CoaguChek

The CoaguChek® INRange and CoaguChek® XS systems are easy-to-use INR self-testing meters that give you fast and accurate results without having to visit the clinic.18,19 Your doctor will be able to receive and monitor your results, so when your dose does need changing, you can find out sooner.

Three easy steps to INR self-monitoring with CoaguChek

IN range

1. Measure your INR levels with a CoaguChek device

A doctor sitting at a desk, looking down at a computer screen.

2. Results are received and analyzed by your doctor

An elderly woman standing outside, smiling and holding up a mobile phone to her ear

3. Therapy decision is made

Say yes to more me time: Discover the benefits of INR self-testing

More freedom: Test your INR anywhere and anytime with immediate results that are comparable to those you would get from the lab.18-19  At-home INR testing can lead to fewer visits to the laboratory, no waiting for test results, and fewer calls or visits to your doctor for dose adjustment decisions.11,20,21

More control: Gain better control of your anticoagulation therapy. Compared to having your INR values tested in the laboratory or anticoagulation clinic, INR self-testing can also lead to more time in your therapeutic range and fewer incidents of very high or low INR values.12,15,16,22

Better care: Studies show that INR self-testing can lead to improved health and quality of life and better treatment satisfaction.11-13,15,23-26

CoaguChek® INRange

The CoaguChek® INRange system for patient INR value self-testing, gives patients confident control of their VKA therapy for more time in therapeutic range.

CoaguChek® XS system

The CoaguChek® XS provides quantitative prothrombin time testing for the monitoring of warfarin therapy, giving fast and reliable results anywhere at any time.

Contact us

Do you have questions about our products or services? We’re here to help. Contact a Roche representative in your region.

Contributors

Omai Garner headshot

Roche Diagnostics

Roche Diagnostics is a division of Roche, developing and integrating diagnostic solutions that address today’s healthcare challenges while anticipating tomorrow’s needs. In more than 100 countries, we provide one of the industry’s most comprehensive in vitro diagnostics portfolios spanning molecular diagnostics, clinical chemistry and immunoassays, tissue diagnostics, Point of Care testing, patient self-testing, next-generation sequencing, laboratory automation and IT, as well as digital health and decision-support solutions.

Our articles are authored by Roche Diagnostics subject matter experts, drawing on collective expertise across multiple disciplines to provide reliable insights for healthcare professionals worldwide.

Explore articles from our community

Contact us

Do you have questions about our products or services? We’re here to help. Contact a Roche representative in your region.

References
 
  1. Ryan F, et al. Managing oral anticoagulation therapy: improving clinical outcomes. A review. J Clin Pharm Ther. 2008;33:581-590.
  2. Stevens SM, et al. Guidance for the evaluation and treatment of hereditary and acquired thrombophilia. J Thromb Thrombolysis. 2016;41(1):154-164.
  3. Lip GYH, et al. Antithrombotic therapy for atrial fibrillation. BMJ. 2002;325(7371):1022-1025.
  4. Wardrop D and Keeling D. The story of the discovery of heparin and warfarin. Br J Haem. 2008;141(6):757–763.
  5. Institute for Quality and Efficiency in Health Care (IQWIG). In brief: How can you monitor and adjust treatment with vitamin K antagonists? [Book; 2017; updated 2022 Oct; cited 2026 Feb 16]. Available from: https://www.ncbi.nlm.nih.gov/books/NBK279434/
  6. Shikdar S, et al. International Normalized Ratio: Assessment, Monitoring, and Clinical Implications [Book; 2018; cited 2026 Feb 16]. Available from: https://www.ncbi.nlm.nih.gov/books/NBK507707/
  7. Tidman et al. (2015). Aust Precr 38, 44-48.
  8. American Heart Association. A guide to taking Warfarin [Internet; cited 2026 Feb 16]. Available from: https://www.heart.org/en/health-topics/arrhythmia/prevention--treatment-of-arrhythmia/a-patients-guide-to-taking-warfarin
  9. Vasculearn Network (VLN). A Guide to INR Levels [Internet; updated 2024 Apr; cited 2025 Dec]. Available from:https://thrombosis.org/patients/patient-articles/a-guide-to-inr-levels
  10. Ufer M.Comparative pharmacokinetics of vitamin K antagonists: warfarin, phenprocoumon and acenocoumarol. Clin Pharmacokinet. 2005;44(12):1227-1246.
  11. Sharma P, et al. The clinical effectiveness and cost-effectiveness of point-of-care tests (CoaguChek system, INRatio2 PT/INR monitor and ProTime Microcoagulation system) for the self-monitoring of the coagulation status of people receiving long-term vitamin K antagonist therapy, compared with standard UK practice: systematic review and economic evaluation. Health Technol Assess. 2015;19(48):1-172.
  12. Garcia-Alamino JM, et al. Self-monitoring and self-management of oral anticoagulation. Cochrane Database Syst Rev. 2010;(4):CD003839.
  13. Christensen TD, et al. Self-Management of Anticoagulant Therapy in Mechanical Heart Valve Patients: A Matched Cohort Study. Ann Thorac Surg. 2016;101(4):1494–1499.
  14. Heneghan CJ, et al. Self-monitoring and self-management of oral anticoagulation. Cochrane Database Syst Rev. 2016;7(7):CD003839.
  15. Soliman Hamad MA, et al. Self-management program improves anticoagulation control and quality of life: a prospective randomized study. Eur J Cardiothorac Surg. 2009;35(2):265-269
  16. Siebenhofer A, et al. Thromb Haemost. 2007;97(3):408-416.
  17. F. Hoffmann-La Roche Ltd. CoaguCheck XS PST Test Package Insert. (v7.1). 2021.
  18. Plesch W and  van den Besselaar AM. Validation of the international normalized ratio (INR) in a new point-of-care system designed for home monitoring of oral anticoagulation therapy. Int J Lab Hematol. 2009;31:20-25.
  19. 19. Ryan F, et al. The reliability of point-of-care prothrombin time testing. A comparison of CoaguChek S and XS INR measurements with hospital laboratory monitoring. Int J Lab Hematol. 2010;32(1):e26–e33.
  20. Grunau BE, et al. Patient self-management of warfarin therapy. Can Fam Physician. 2011;57(8):e292-e298.
  21. Bloomfield HE, et al. Meta-analysis: effect of patient self-testing and self-management of long-term anticoagulation on major clinical outcomes. Ann Intern Med. 2011;154(7):472-482.
  22. Dignan R, et al. Is home warfarin self-management effective? Results of the randomised Self-Management of Anticoagulation Research Trial. Int J Cardiol. 2013;168(6):5378-5384.
  23. Heneghan C, et al. Self-monitoring of oral anticoagulation: systematic review and meta-analysis of individual patient data. Lancet. 2012;379(9813):322-334.
  24. Tamayo Aguirre E, et al. Oral anticoagulation with vitamin K inhibitors and determinants of successful self-management in primary care. BMC Cardiovasc Disord. 2016;16(1):180.
  25. Verret L, et al. Impact of a Pharmacist-Led Warfarin Self-Management Program on Quality of Life and Anticoagulation Control: A Randomized Trial. Pharmacotherapy. 2012;32(10):871-879.
  26. Siebenhofer A, et al. Self-management of oral anticoagulation in elderly patients - effects on treatment-related quality of life. Thromb Res. 2012;130(3):e60–e66.